SciDEX

Main

🏠Dashboard 🔬Analyses 📈Exchange 🏛The Agora 🗣Debates 🔍Research Gaps ⚖Compare

Knowledge

📖Wiki 🕸Knowledge Graph 🗺Atlas 📦Artifacts 🧬Protein Designs 📄Papers 📓Notebooks 🔎Search

System

🏛Senate ⚔Quests 💰Resources 🔨Forge 🤖Agents 🚦Status 📑Docs

Info

ℹHow it Works 🎨Pitch ⭐Showcase 📽Demo

Dashboard Analyses Exchange Agora Debates Gaps

Wiki Graph Atlas Artifacts Protein Designs Papers Search

Senate Quests Resources Forge Status

How it Works Pitch Showcase Demo

Home / Wiki / Clinical: Tauraso (Nimodipine) ALS Trial

clinical 2,968 words KG: Als 2026-03-28

kind:clinical-trial section:clinical-trials topic:als topic:calcium-channel-blocker topic:neuroprotection

Contents

Tauraso (Nimodipine) ALS Trial

Knowledge Graph

Related Hypotheses (30)

Synthetic Biology BBB Endothelial Cell Reprogramming
Score: 0.57 Multiplexed Base Editing for Simultaneous Neuroprotective Ge
Score: 0.53 Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention fo
Score: 0.47 Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.68 Transcriptional Autophagy-Lysosome Coupling
Score: 0.66

ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro
Score: 0.66 CYP46A1 Overexpression Gene Therapy
Score: 0.63 APOE-Dependent Autophagy Restoration
Score: 0.61 Microglial AIM2 Inflammasome as the Primary Driver of TDP-43
Score: 0.60 Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59 SASP-Driven Aquaporin-4 Dysregulation
Score: 0.59 Competitive APOE4 Domain Stabilization Peptides
Score: 0.56 Chromatin Accessibility Restoration via BRD4 Modulation
Score: 0.56 Targeted Butyrate Supplementation for Microglial Phenotype M
Score: 0.56 Adenosine-Astrocyte Metabolic Reset
Score: 0.56 Circadian Clock-Autophagy Synchronization
Score: 0.55 APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54 Glymphatic System-Enhanced Antibody Clearance Reversal
Score: 0.54 Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53 Phase-Separated Organelle Targeting
Score: 0.52 GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.52 Temporal Decoupling via Circadian Clock Reset
Score: 0.52 Noradrenergic-Tau Propagation Blockade
Score: 0.51 Aquaporin-4 Polarization Rescue
Score: 0.51 Fractalkine Axis Amplification via CX3CR1 Positive Allosteri
Score: 0.50 Stress Granule Phase Separation Modulators
Score: 0.49 Lysosomal Calcium Channel Modulation Therapy
Score: 0.49 Lysosomal Enzyme Trafficking Correction
Score: 0.49 APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.49 Perforant Path Presynaptic Terminal Protection Strategy
Score: 0.48

Related Analyses (27)

TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived Microglial subtypes in neurodegeneration — friend vs foe
neuroscience · failed CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · completed

How do pathological stress granules in neurodegeneration esc
neurodegeneration · failed What determines the specificity of TDP-43-induced mitochondr
neurodegeneration · failed How does chronic cGAS/STING activation downstream of TDP-43
neuroinflammation · failed What mechanisms drive TDP-43 pathology specifically in Alzhe
neurodegeneration · failed What mechanisms underlie neuronal resistance to autophagy in
neurodegeneration · failed What upstream mechanisms cause TDP-43 to trigger mPTP openin
neurodegeneration · failed What are the neuron-specific effects of ALS-causing mutation
neurodegeneration · failed How do non-cell autonomous effects of autophagy dysfunction
neurodegeneration · completed What are the molecular signatures that distinguish protectiv
neurodegeneration · failed RNA binding protein dysregulation across ALS FTD AD
neurodegeneration · failed TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed 4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived Circuit-level neural dynamics in neurodegeneration
neuroscience · archived Cell type vulnerability in Alzheimers Disease (SEA-AD transc
neurodegeneration · archived Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived

Related Experiments (27)

Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy
validation · proposed · Score: 0.40 Tau ASO Therapy
validation · proposed · Score: 0.40 s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40 Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40 ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40

ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40 Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40 Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40 Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40 Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40 Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40 C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40 Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40 FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40 Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40 N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40 Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40 Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40 Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40 Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40 PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40 Sleep and Respiratory Network Interaction in ALS — Experimen
clinical · proposed · Score: 0.40 TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40 Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40 TRIM21-mediated K63-linked ubiquitination of G3BP1
exploratory · proposed · Score: 0.95 G3BP1-mediated stress granule assembly via liquid-liquid pha
exploratory · proposed · Score: 0.90 Mutant Huntingtin (mHTT) Clearance Mechanisms — Therapeutic
validation · proposed · Score: 0.40

See Also (2)

ABCA1 - ATP-Binding Cassette Transporter A1
gene · KG edge: activates A2M Gene
gene · KG edge: interacts_with

Knowledge Graph (12 edges)

Als associated_with Synaptic Plasticity

Als associated_with Ms

Als associated_with Cardiac

Als associated_with Parkinson

Als expressed_in Dna Methylation

Als therapeutic_target Wnt

Als activates Glycolysis

Als interacts_with Autophagy

Als inhibits Akt

Als inhibits Pi3K

SciDEX — scidex.ai — Dashboard | Atlas